The EPISODE trial of psychedelic-assisted therapy for ‘treatment-resistant depression’ finds only modest effects, with a few clear responders, but lingering methodological questions.
[read the full story...]
A single dose of tocilizumab cleared inflammation in depressed patients, but did it ease their symptoms? A proof-of-concept RCT with cautious promise.
[read the full story...]
Psychedelic therapy looks impressive in trials, but when you account for the placebo effect, how does it really compare to antidepressants?
[read the full story...]
Once symptoms stabilise after a first episode of psychosis, should medication continue? A four-year RCT explores the risks and rewards of dose reduction.
[read the full story...]
Four recent reviews all agree: we still don’t know how to define, measure, or improve engagement with digital mental health interventions.
[read the full story...]
Oxytocin alone didn’t speed wound healing in couples, but combined with affectionate touch and partner appreciation, it showed modest benefits. Social context matters more than hormones.
[read the full story...]
Recent research suggests that lower IQ and cognitive performance link to higher alcohol use disorder risk, but education and societal factors can amplify or reduce this vulnerability, not genetics alone.
[read the full story...]
Sexual assault survivors face six-fold increased risk of multiorgan functional somatic disorder (unexplained physical symptoms like chronic pain and fatigue).
[read the full story...]
A big new study suggests that certain genetic traits—like insomnia risk and neuroticism—may make depression harder to treat, while protective traits include education and cognitive ability.
[read the full story...]
Effective treatment for mental health disorders remains the exception rather than the rule. A new 21-country study reveals where in the treatment cascade people are most likely to drop out and which factors improve the odds of getting the care they need.
[read the full story...]
